KR20090014300A - 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성솔루션과 준비방법 - Google Patents

20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성솔루션과 준비방법 Download PDF

Info

Publication number
KR20090014300A
KR20090014300A KR1020087031196A KR20087031196A KR20090014300A KR 20090014300 A KR20090014300 A KR 20090014300A KR 1020087031196 A KR1020087031196 A KR 1020087031196A KR 20087031196 A KR20087031196 A KR 20087031196A KR 20090014300 A KR20090014300 A KR 20090014300A
Authority
KR
South Korea
Prior art keywords
ginsenoside
solution
aqueous solution
combination
accessory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087031196A
Other languages
English (en)
Korean (ko)
Inventor
리 푸
홍 리우
밍밍 루
키 루
조성태
완제 쿠이
Original Assignee
리 푸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리 푸 filed Critical 리 푸
Publication of KR20090014300A publication Critical patent/KR20090014300A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020087031196A 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성솔루션과 준비방법 Ceased KR20090014300A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006100466172A CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法
CN200610046617.2 2006-05-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011500A Division KR101221680B1 (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법

Publications (1)

Publication Number Publication Date
KR20090014300A true KR20090014300A (ko) 2009-02-09

Family

ID=37581875

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087031196A Ceased KR20090014300A (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성솔루션과 준비방법
KR1020127011500A Expired - Fee Related KR101221680B1 (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127011500A Expired - Fee Related KR101221680B1 (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법

Country Status (10)

Country Link
US (2) US8487090B2 (https=)
EP (1) EP2025339B1 (https=)
JP (1) JP5525814B2 (https=)
KR (2) KR20090014300A (https=)
CN (1) CN1883492B (https=)
AU (1) AU2007252183B2 (https=)
CA (1) CA2653085C (https=)
ES (1) ES2477873T3 (https=)
RU (1) RU2432164C2 (https=)
WO (1) WO2007134534A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101316095B1 (ko) * 2013-01-30 2013-10-11 경희대학교 산학협력단 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN101530389B (zh) * 2008-03-11 2012-02-15 沈阳市万嘉生物技术研究所 人参皂苷Rg3磷脂复合物及其制备方法
CN102091114B (zh) * 2009-12-15 2014-11-26 河北以岭医药研究院有限公司 一种中药冻干注射剂及其制备方法
KR100992800B1 (ko) * 2010-05-14 2010-11-08 주식회사 지씨에이치앤피 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법
CN103845280B (zh) * 2012-11-30 2017-04-12 富力 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途
CN103845348B (zh) * 2012-11-30 2016-07-13 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用
KR102021463B1 (ko) * 2013-04-24 2019-09-16 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR101595426B1 (ko) 2013-08-30 2016-02-18 (주)녹십자웰빙 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물
CN104643058A (zh) * 2013-11-21 2015-05-27 富力 20(R)-人参皂苷Rg3在制备改善或/和治疗肝硬化疾病的药物中的应用
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
CN105012315A (zh) * 2014-04-24 2015-11-04 上海中医药大学 20(r)-原人参二醇的医药用途
CN105777838A (zh) * 2014-12-17 2016-07-20 富力 20(R)-人参皂苷Rg3衍生物、制备方法及其应用
CN105982906A (zh) * 2015-02-11 2016-10-05 富力 20(R)-人参皂苷Rg3在制备缓解或/和治疗类风湿病症的药物或保健品中的应用及药物
KR101772759B1 (ko) 2015-09-25 2017-08-30 순천향대학교 산학협력단 안정화된 무정형의 20(R)-진세노사이드 Rg3, 이의 제조방법 및 이를 함유하는 약제학적 제제
CN105878206A (zh) * 2016-03-31 2016-08-24 北京万全德众医药生物技术有限公司 一种人参皂苷Rg3的软胶囊及其制备方法
KR20180000379A (ko) * 2016-06-22 2018-01-03 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물
CN108310106A (zh) * 2018-03-30 2018-07-24 吉林省恒实传食品科技发展有限公司 一种补肾填髓、健脑益智、辅助改善记忆的中药组合物及其应用
KR20200112012A (ko) * 2019-03-20 2020-10-05 순천대학교 산학협력단 (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물
CN111686104A (zh) * 2020-07-01 2020-09-22 香港浸会大学深圳研究院 小白菊内酯、木犀草素、金圣草素和人参皂苷Rg3的新用途
CN112245443A (zh) * 2020-08-25 2021-01-22 富力 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用
CN116077442A (zh) * 2023-01-06 2023-05-09 吉林大学 一种含有人参皂苷Rg3的纳米颗粒及其制备方法和应用
KR102756809B1 (ko) * 2023-10-13 2025-01-22 표재성 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186015C (zh) 2001-01-18 2005-01-26 天津实验动物中心 用于冠心病心绞痛的中药复方口腔贴膜
CN1167734C (zh) * 2001-07-02 2004-09-22 董英杰 人参皂甙Rg3羟丙基-β-环糊精包合物及制剂和制备方法
CN1526405A (zh) * 2003-01-06 2004-09-08 山东绿叶天然药物研究开发有限公司 抗肿瘤的人参皂苷Rg3注射剂及其制备方法
CN1569012A (zh) * 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用
CN1569011A (zh) 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20（R）－人参皂苷－Rg3在制备治疗或预防心脑血管疾病的药物中的应用
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101316095B1 (ko) * 2013-01-30 2013-10-11 경희대학교 산학협력단 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물

Also Published As

Publication number Publication date
EP2025339A1 (en) 2009-02-18
RU2008150468A (ru) 2010-06-27
JP2009537572A (ja) 2009-10-29
AU2007252183B2 (en) 2013-07-11
KR20120054664A (ko) 2012-05-30
US9333215B2 (en) 2016-05-10
CA2653085C (en) 2016-01-19
US20130345156A1 (en) 2013-12-26
CN1883492B (zh) 2010-07-28
CN1883492A (zh) 2006-12-27
ES2477873T3 (es) 2014-07-18
KR101221680B1 (ko) 2013-01-11
JP5525814B2 (ja) 2014-06-18
AU2007252183A1 (en) 2007-11-29
US20120149656A1 (en) 2012-06-14
US8487090B2 (en) 2013-07-16
WO2007134534A1 (fr) 2007-11-29
RU2432164C2 (ru) 2011-10-27
EP2025339A4 (en) 2013-01-16
CA2653085A1 (en) 2007-11-29
EP2025339B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
KR101221680B1 (ko) 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법
CN108245496B (zh) 虾青素抗炎增效组合
KR101512495B1 (ko) 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도
CN101524331A (zh) 一种多糖脂质体、其制备方法及用途
JP6209579B2 (ja) 補助化療薬品とされる医薬組成物その用途
CN102058536A (zh) 槲皮素羟丙基β－环糊精包和物脂质体及其制备方法和用途
CN114831931A (zh) 一种具有抗肿瘤增效减毒效果的药用溶液及包含其的药用组合物
JPS61151123A (ja) 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
CN101496811B (zh) 一种可溶且稳定的替米考星组合物
CN104688722B (zh) 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途
CN101612159A (zh) 化合物20(S)-人参皂苷Rh2在制备抗疲劳药物中的应用
CN117224670B (zh) 一种脂质体佐剂组合物、疫苗组合物及其制备方法和应用
CN110772564A (zh) 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂
KR20090131577A (ko) 글루코사민과 생약재 혼합물을 포함하는 약학 제제
Atef et al. Influence of aflatoxin B1 on the kinetic disposition, systemic bioavailability and tissue residues of doxycycline in chickens
KR20200144568A (ko) 통증 및/또는 발열을 예방 및/또는 치료하는 의약품, 조합 산물 및 그 응용
Polova Study of acute toxicity of a new veterinary drug for inttrammary introduction
CN102579419B (zh) 绿原酸的抗癌用途
Eward et al. Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study
CN108057049A (zh) 一种增强细胞活力的中药组合物及其制备方法
CN105232465A (zh) 一种芬苯达唑脂质体制剂及其制备方法
CN108815239B (zh) 一种药物组合物在制备抗菌药物中的应用
CN107029240A (zh) 树枝状大分子聚酰胺‑胺在吴茱萸碱中的用途
DE102016121050A1 (de) Erzeugnis in Tablettenform bzw. Erzeugnis in Kapselform enthaltend eine trockene Darreichungsform einer GcMAF-enthaltenden Formulierung
TWI918004B (zh) 用於預防、改善及／或治療肌肉疾病或肌肉失調之組合

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20081222

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101115

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101115

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110830

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110729

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120816

Appeal identifier: 2011101006207

Request date: 20110830

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110929

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110830

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110117

Patent event code: PB09011R02I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120503

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20120703

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20120816

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20120816

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2011101006207

Request date: 20110830

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120816

WITB Written withdrawal of application